The obesity pipeline: current strategies in the development of anti-obesity drugs
- 1 November 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (11) , 919-931
- https://doi.org/10.1038/nrd2136
Abstract
This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.Keywords
This publication has 132 references indexed in Scilit:
- Vaccination against weight gainProceedings of the National Academy of Sciences, 2006
- Absence of ghrelin protects against early-onset obesityJournal of Clinical Investigation, 2005
- WAY-163909 [(7 bR, 10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjectsBritish Journal of Nutrition, 2004
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- Sibutramine: its mode of action and efficacyInternational Journal of Obesity, 2002
- The cannabinoid receptorsProstaglandins & Other Lipid Mediators, 2002
- Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin DeficiencyNew England Journal of Medicine, 1999
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Action of Growth Hormone in Adipose TissueHormone Research, 1997